Abstract:Natural killer (NK) cell-based immunotherapy represents a promising strategy to overcome the bottlenecks of cancer treatment. However, the therapeutic efficacy is greatly limited by downregulation of recognition ligands on the tumor cell surface, and the immunosuppressive effects can be thwarted by the tumor microenvironment such as secretion of transforming growth factor-beta (TGF-β), which could stunt the NK cell-mediated immune response. To overcome these limitations, herein we developed a nanoemulsion system (SSB NMs) to co-deliver TGF-β inhibitor and selenocysteine (SeC) to achieve amplified anticancer efficacy. SSB NMs significantly enhanced the lytic potency of NK92 cells by 2.1-fold. Moreover, a subtoxic dose of SSB NMs effectively sensitized MDA-MB-231 triple-negative breast cancer (TNBC) cells to NK cells derived from seven clinical patients, resulting in an up to 13.8-fold increase in cancer lysis. Mechanistic studies reveal that the sensitizing effects relied on natural killer group 2, member D (NKG2D)/NKG2D ligands (NKG2DLs) signaling with the involvement of DNA damage response. SSB NMs also effectively restrained TGF-β/TGF-β RI/Smad2/3 signaling, which thus enhanced NKG2DL expression on tumor cells and stimulated NKG2D surface expression on NK92 cells, ultimately contributing to the enhanced immune response. Furthermore, SSB NMs sustained release of SeC and TGF-β inhibitor and synergized with NK92 cells to induce significant anticancer effects <i>in vivo</i>. Together, this study not only demonstrates a simple strategy for the design of a nanoemulsion to co-deliver synergistic drugs but also sheds light on the application and action mechanisms in NK cell adaptive therapy against breast cancer, especially TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.9b10103?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.9b10103</a>.Figures of the immunosensitizing effects of NK92 cells induced by SSB NMs against MDA-MB-231 cancer cells; cytolytic activities of NK92 cells after preincubated with SeC against cancer cells; SSB NMs augment the cytolytic activities of NK92 cells on HCC1937 and MDA-MB-468 cells; SSB NMs augment the cytolytic activities of NK92 cells by determining LDH release; characterization of NK cells from patients; cellular uptake and intracellular localization of Cou6-labeled and SSB NMs in MDA-MB-231 cells; expression of DR4/5, TRAIL, and FasL; comet assay and immunocytochemistry detecting DNA damage; cell cycle analysis by flow cytometry; antimigration effects of SeC and SSB NMs; tumor images and tumor inhibition ratio; hematological analysis; H&E-stained images of major organs; H&E-stained images and clinical chemistry evaluation in orthotopic tumor model (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.9b10103/suppl_file/nn9b10103_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Therapeutic effect of small extracellular vesicles from cytokine-induced memory-like natural killer cells on solid tumors

Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases

Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18

Opportunities and challenges of natural killer cell-derived extracellular vesicles

Extracellular Vesicles From the Human Natural Killer Cell Line NK3.3 Have Broad and Potent Anti-Tumor Activity

Cytokine-enhanced cytolytic activity of exosomes from NK Cells

Enhancing non-small cell lung cancer treatment utilizing natural killer cell-derived extracellular vesicles (NKEVs) as a novel adoptive cellular therapeutic.

Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery

Reprogramming of T cell‐derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery

An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy

Scale-out Production of Extracellular Vesicles Derived from Natural Killer Cells Via Mechanical Stimulation in a Seesaw-Motion Bioreactor for Cancer Therapy.

Tropism of Extracellular Vesicles and Cell-Derived Nanovesicles to Normal and Cancer Cells: New Perspectives in Tumor-Targeted Nucleic Acid Delivery

Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion

Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy

Extracellular vesicles derived from immune cells: Role in tumor therapy

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance

The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy

Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice

Natural Killer Cell‐Derived Extracellular Vesicles as Potential Anti‐Viral Nanomaterials

Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy